The FDA has lifted a hold on clinical studies involving the investigational therapy fitusiran.
This agreement allows Shire to conduct research on the use of Rani Pill™ technology for the oral delivery of factor VIII therapy for patients with hemophilia A.
Spark provided clinical trial updates on the company’s investigational gene therapies for hemophilia A and B, SPK-8011 and SPK-9001.
Genentech recently reported results from the phase III HAVEN 3 study, which showed that the prophylactic use of HEMLIBRA® led to significantly reduced bleeds in adult and adolescent patients with h
The study will evaluate the use of Eloctate™ for immune tolerance induction (ITI) therapy in hemophilia A patient with inhibitors.
Rofecoxib is a class of COX-2 selective non-steroidal anti-inflammatory drug (NSAID) for the treatment of hemophilic arthropathy.
Alnylam is developing the therapy to treat patients with hemophilia A and B, both with and without inhibitors.
People who used the therapy for nearly three years saw regular improvements in their joint health.
The BLA was submitted in light of positive data yielded from a phase 2/3 clinical study.
The breakthrough status was granted in light of positive results of phase 1/2 clinical study.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car